Accuray Overview
- Year Founded
-
1990
- Status
-
Public
- Employees
-
809
- Stock Symbol
-
ARAY
- Investments
-
4
- Share Price
-
$2.07
- (As of Friday Closing)
Accuray General Information
Description
Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, treatment solutions which set the standard of radiation therapy care with the objective of helping patients live lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention. The company has one operating segment which develops, manufactures and markets proprietary medical devices used in radiation therapy for the treatment of cancer patients.
Contact Information
Website
www.accuray.comCorporate Office
- 1240 Deming Way
- Madison, WI 53717-1954
- United States
Corporate Office
- 1240 Deming Way
- Madison, WI 53717-1954
- United States
Accuray Timeline
Accuray Stock Performance
As of 20-Nov-2026, Accuray’s stock price is $2.07. Its current market cap is $6.22M with 3M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.07 | $2.12 | $2.05 - $45.20 | $6.22M | 3M | 199K | -$6.00 |
Accuray Financials Summary
As of 30-Sep-2026, Accuray has a trailing 12-month revenue of $395M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2026 30-Jun-2026 | FY 2025 30-Jun-2025 | FY 2024 30-Jun-2024 |
|---|---|---|---|---|
| EV | 175,512 | 174,999 | 289,840 | 327,164 |
| Revenue | 394,528 | 401,947 | 458,505 | 446,551 |
| EBITDA | 28,906 | (7,220) | 19,046 | 4,478 |
| Net Income | (17,382) | (49,194) | (1,591) | (15,545) |
| Total Assets | 390,055 | 443,676 | 470,239 | 468,627 |
| Total Debt | 135,974 | 183,874 | 176,377 | 210,747 |
Accuray Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Accuray Comparisons
Industry
Financing
Details
Accuray Competitors (17)
One of Accuray’s 17 competitors is OncoDNA, a Venture Capital-Backed company based in Gosselies, Belgium.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| OncoDNA | Venture Capital-Backed | Gosselies, Belgium | ||||
| eCential Robotics | Venture Capital-Backed | Gieres, France | ||||
| Varian Medical Systems | Venture Capital-Backed | Palo Alto, CA | ||||
| ZAP Surgical | Venture Capital-Backed | San Carlos, CA | ||||
| ViewRay | Formerly VC-backed | Bedford, OH |
Accuray Patents
Accuray Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026035438-A1 | Dynamic volume registration for image-guided radiotherapy | Pending | 09-Aug-2024 | ||
| WO-2026015276-A1 | Efficient medical dataset presentation | Pending | 10-Jul-2024 | ||
| WO-2026006077-A1 | Apparatus and method of generating beam control data based on imaging uncertainty | Pending | 28-Jun-2024 | ||
| WO-2026006082-A1 | Apparatus and method of image deformation based on imaging uncertainty | Pending | 28-Jun-2024 | ||
| JP-2024156622-A | Fundamental of semi-conductor-based photon counting detector | Pending | 24-Apr-2023 | A61B6/44 |
Accuray Signals
Accuray Investments & Acquisitions (4)
Accuray’s most recent deal was a Joint Venture with CNNC Accuray (Tianjin) Medical Technology. The deal was made on 28-Jan-2019.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| CNNC Accuray (Tianjin) Medical Technology | 28-Jan-2019 | Joint Venture | Therapeutic Devices | ||
| Morphormics | 16-Jul-2012 | Merger/Acquisition | Other Healthcare Technology Systems | ||
| Compact Particle Acceleration | 16-May-2012 | Early Stage VC | Therapeutic Devices | ||
| TomoTherapy | 13-Jun-2011 | Merger/Acquisition | Therapeutic Devices |
Accuray ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
30.01 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Healthcare
Industry
of 590
Rank
Percentile
Medical Devices
Subindustry
of 209
Rank
Percentile
Accuray Exits (1)
Accuray’s most recent exit was on 16-May-2012 from Compact Particle Acceleration. The exit was categorized as with 4 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Compact Particle Acceleration | 16-May-2012 | Completed |
|
Accuray FAQs
-
When was Accuray founded?
Accuray was founded in 1990.
-
Where is Accuray headquartered?
Accuray is headquartered in Madison, WI.
-
What is the size of Accuray?
Accuray has 809 total employees.
-
What industry is Accuray in?
Accuray’s primary industry is Other Devices and Supplies.
-
Is Accuray a private or public company?
Accuray is a Public company.
-
What is Accuray’s stock symbol?
The ticker symbol for Accuray is ARAY.
-
What is the current stock price of Accuray?
As of 20-Nov-2026 the stock price of Accuray is $2.07.
-
What is the current market cap of Accuray?
The current market capitalization of Accuray is $6.22M.
-
What is Accuray’s current revenue?
The trailing twelve month revenue for Accuray is $395M.
-
Who are Accuray’s competitors?
OncoDNA, eCential Robotics, Varian Medical Systems, ZAP Surgical, and ViewRay are some of the 17 competitors of Accuray.
-
What is Accuray’s annual earnings per share (EPS)?
Accuray’s EPS for 12 months was -$6.00.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process